key: cord-0725000-zyfmsbfc
authors: Burks, Susan M.; Rosas-Hernandez, Hector; Alenjandro Ramirez-Lee, Manuel; Cuevas, Elvis; Talpos, John C.
title: Can SARS-CoV-2 infect the central nervous system via the olfactory bulb or the blood-brain barrier?
date: 2021-01-04
journal: Brain Behav Immun
DOI: 10.1016/j.bbi.2020.12.031
sha: 1a47ea49004e63a42318e2545c6331af7b73b892
doc_id: 725000
cord_uid: zyfmsbfc

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China in December 2019. On February 11, the World Health Organization (WHO) announced the name for the new illness caused by SARS-CoV-2: COVID-19. By March 11, the outbreak of COVID-19 was declared a pandemic by the WHO. This virus has extensively altered daily life for many across the globe, while claiming hundreds of thousands of lives. While fundamentally a respiratory illness, many infected individuals experience symptoms that involve the central nervous system (CNS). It is likely that many of these symptoms are the result of the virus residing outside of the CNS. However, the current evidence does indicate that the SARS-CoV-2 virus can use olfactory neurons to travel from the periphery into the CNS, and that the virus may also enter the brain through the blood-brain barrier (BBB). We discuss how the virus may use established infection mechanisms (ACE2, TMPRSS2, and Cathepsin L), as well mechanisms still under consideration (NRP1 and BASIGIN) to infect and spread throughout the CNS. Confirming the impact of the virus on the CNS will be crucial in dealing with the long-term consequences of the epidemic.

2 (TMPRSS2), proteins thought to be crucial for the infection and spread of SARS-CoV-2 throughout the body, have low levels of expression in the human brain (Hamming, Timens et al. 2004 ). However new evidence (preprint) indicates that the virus can infect cells via NRP1 or BASIGIN (BSG) (Cantuti-Castelvetri, Ojha et al. 2020 , Daly, Simonetti et al. 2020 and that Cathepsin L (CTSL) can also modify SARS-CoV-1 (Simmons, Gosalia et al. 2005 , Huang, Bosch et al. 2006 ) and SARS-CoV-2 (Ou, Liu et al. 2020 ) to facilitate infection. All these proteins have higher and broader patterns of expression (Atlas 2020) in the human brain than ACE2 or TMPRSS2. This would allow the virus to propagate in the brain, once reaching it 2 .

COVID-19 is primarily a pulmonary disease, and this has driven the consensus that the virus infects cells via ACE2 (Hoffmann, Kleine-Weber et al. 2020, Rothan and Byrareddy 2020) after being modified by TMPRSS2 (Bilinska, Jakubowska et al. 2020 , Hoffmann, Kleine-Weber et al. 2020 ). This focus certainly makes sense as both proteins are expressed at very high levels in the lung making them crucial to the pulmonary pathology of COVID-19 (Atlas 2020) . ACE2 and TMPRSS2 are likely expressed in the brain at low levels (Harmer, Gilbert et al. 2002 , Doobay, Talman et al. 2007 , Xia and Lazartigues 2008 , Baig, Khaleeq et al. 2020 , Bilinska, Jakubowska et al. 2020 ), meaning the virus should in theory be able infect brain cells, and potentially spread throughout the brain. This is in line with preliminary (preprint) (Song, Zhang et al. 2020) and published data showing that SARS-CoV-2 can infect organoid models of the human brain. (Ramani, Muller et al. 2020) . Based off work done in organoid models, the virus should be capable of infecting and spreading in the brain if it can gain access to the brain. However, the total number of cells affected would be limited by the low expression of ACE2, and proximity to TMPRSS2 expressing cells. Unfortunately, evidence indicates that the virus can be modified by multiple proteins such as CTSL (Ou, Liu et al. 2020 , Shang, Ye et al. 2020 . While CTSL may be of minimal importance for pulmonary pathology, it is likely expressed at much higher levels in the brain than TMPRSS2 (Atlas 2020) . This allows for greater viral modification in the brain than would be predicted by the pattern of TMPRSS2 expression alone. Additionally, it is possible that viral entry mechanisms other than ACE2 exist. For example, it has been shown that SARS-CoV-1 could enter cells via BSG (Chen, Mi et al. 2005) , and preliminary evidence (preprint) suggests that the same may be true for SARS-CoV-2 . Furthermore, NRP1 has also been proposed (preprints) as a novel entry mechanism for SARS-CoV-2 (Cantuti-Castelvetri, Ojha et al. 2020 , Daly, Simonetti et al. 2020 . Both proteins are expressed in the brain, including the olfactory bulb (OB), likely at higher levels than ACE2 or TMPRSS2 (Atlas 2020 , Iadecola, Anrather et al. 2020 . Accordingly, SARS-CoV-2 could infect the brain if the virus reaches the brain, potentially via the olfactory epithelium.

The olfactory mucosa of the nasal cavity is made up of olfactory epithelium (OE) containing neurons, two types of basal cells, Bowman's glands, and epithelial cilia (Moran, Rowley et al. 1982 , Iwai, Zhou et al. 2008 , Harkema, Carey et al. 2018 , Liang 2020 . Olfactory sensory neurons (OSN), also known as olfactory receptor neurons, extend through the cribriform plate and target the mitral cells of the OB. Mitral cells have connections to the largest part of the olfactory cortex, the piriform cortex, subsequently projecting to the hippocampus, hypothalamus, and orbital frontal cortex (Fig 1) (Mori, Nagao et al. 1999 , Haberly 2001 , Shepherd 2004 , Buck 2005 , Shepherd 2007 , Heydel, Coelho et al. 2013 . OSNs in humans have an average lifespan of 40 days, with a turnover time of 6 days (Liang 2020) . It is thought that "new" OSNs arise from a population of immature neurons, horizontal basal cells (HBC) (Brann and Firestein 2014) . HBCs are attached directly to the basal lamina and are the progenitors of OSN and globus basal cells, which are located above the HBC (Iwai, Zhou et al. 2008 , Harkema, Carey et al. 2018 . Basal cells also give rise to the sustentacular cells that span the entire thickness of the OE (Harkema, Carey et al. 2018) . Sustentacular cells are thought to be a mix of glial and epithelial cells. These cells support the OE and OSN metabolism, making them crucial in olfaction (Liang 2020) . When compared to HBCs, sustentacular cells are thought to have a longer life span and a slower turnover time (Arslan 2014) . It has been shown that sustentacular cells (human) express ACE2 and TMPRSS2 at high levels (Bilinska, Jakubowska et al. 2020) . These cells are vulnerable to SARS-CoV-2 infection, (Bryche, St Albin et al. 2020) , which may explain the high incidence of anosmia in COVID-19 Butowt 2020, Gupta, Mohanty et al. 2020) . Once infected, sustentacular cells would bath HBCs in virus, providing a second, and potentially more worrisome route to anosmia arising from infection of the OB.

Although ACE2 has not been reported in mature olfactory nerves (human) and is likely present at low levels in neurons (Harmer, Gilbert et al. 2002) and is believed to be expressed in HBCs which mature into OSN (Hamming, Timens et al. 2004 , Hamming, Cooper et al. 2007 , Fletcher, Das et al. 2017 , Bilinska, Jakubowska et al. 2020 3 . HBCs are surrounded by OE. An infection of the OE would likely spread to HBCs and subsequently immature and mature olfactory neurons as observed in the hamster (Zhang, Lee et al. 2020) . As infected HBCs mature into OSN, they have a synaptic path to the OB, thereby a potential route of CNS infection (Barnett, Cassell et al. 1993) . It would take relatively few infected OSNs to spread the infection to the OB. Through this route, a peripheral infection could reach the OB and from there, move throughout the brain. Once in the brain, a cycle of viral budding and neuronal damage is possible. Additionally, damage to the BBB, neuronal inflammation triggered by systemic infection, and stroke/hemorrhage may contribute to the outcomes of COVID-19 patients presenting with CNS symptoms.

The critical role of the olfactory nerve and OB as a transient in CNS viral transmission has been demonstrated for multiple viruses (Monath, Cropp et al. 1983 , Lafay, Coulon et al. 1991 , Mori, Komatsu et al. 1995 , Yamada, Nakamura et al. 2009 ), including the mouse hepatitis virus (MHV), which is also a coronavirus (Perlman, Evans et al. 1990 ). Ablation of the OB blocked the development of CNS infection in mice that received an intranasal inoculation with MHV (Perlman, Evans et al. 1990 ). MHV, however, is thought to bind with carcinoembryonic antigen-related cell adhesion molecule 1 rather than ACE2. Regardless, those data show the spread of infection throughout the CNS is, in some instances, predicated on an infection of the OB. The OB also plays a key role in the spread of ACE2-dependent coronavirus infections (SARS-CoV-1). Mice expressing the human ACE2 receptor were intra-nasally treated with SARS-CoV-1, and soon after (60-66 hours) antibodies were detected in the OB, some cortical areas, and parts of the basal ganglia (Netland, Meyerholz et al. 2008) . Four days after the initial exposure, the infection had spread to the medulla, pons, midbrain, thalamus, hypothalamus, amygdala, hippocampus, basal ganglia, cortex, and through most of the OB. Those data demonstrate that a coronavirus will "pass through" the OB in the process of infecting more distal regions of the brain. (Netland, Meyerholz et al. 2008 ). In the hamster, SARS-CoV-2 has been shown to infect olfactory nerves (Sia, Yan et al. 2020 , Zhang, Lee et al. 2020 ) and the brain (Bryche, St Albin et al. 2020 , Chan, Zhang et al. 2020 , Zhang, Lee et al. 2020 . These data show that an infection which reaches the OB can quickly spread throughout the brain. Low levels of ACE2 in the human brain would limit the impact on the CNS if no other cell entry mechanisms are discovered. However, if other viral entry methods, such as NRP1 or BSG, are confirmed the potential for viral mediated CNS damage will be much greater.

Human data on SARS-CoV-1 or 2 brain infections are less extensive than that in the rodent literature. The first reported case of a CNS SARS-CoV-1 infection is from 2003 (Hung, Chim et al. 2003) when the SARS-CoV-1 virus was detected in the cerebrospinal fluid of a patient. Several other case reports of CNS infection in SARS-CoV-1 infections soon followed (Lau, Yu et al. 2004 , Yeh, Collins et al. 2004 . A postmortem study of individuals who died from SARS-CoV-1 found evidence of the virus in the brains of all four individuals investigated (Ding, He et al. 2004) . Data are very limited on SARS-CoV-2 infections in the human CNS. Interestingly, the first description of the virus in the human CNS was in an individual who tested negative for the virus via nasal swab (Moriguchi, Harii et al. 2020) . A larger post-mortem study investigating the multiorgan tropism of SARS-CoV-2 reported that 8 of 27 patients had signs of CNS infection, but in only two of those instances was the virus also detected in the blood (Puelles, Lutgehetmann et al. 2020 ). While that sample was small, these data suggest that instances of CNS infection can occur via the hematogenous route in a limited number of cases (via the blood-brain barrier, BBB).

In addition to potential brain infection via the olfactory route, it is likely that SARS-CoV-2 can access the brain via the hematogenous route (Desforges, Le Coupanec et al. 2019) . Reports indicating damage to lung blood vessels caused by SARS-CoV-2 have emerged , Lang, Som et al. 2020 , Magro, Mulvey et al. 2020 . Post-mortem analysis of the lungs of COVID-19 patients revealed that endothelial necrosis and capillary injury can occur after SARS-CoV-2 infection with viral proteins detected in the lung capillaries , Magro, Mulvey et al. 2020 . This suggests that SARS-CoV-2 can be translocated from the lungs to the pulmonary microcirculation, and then spread throughout the body and potentially infect other organs, including the brain (Fig. 2) . Although reported in only a small number of patients, SARS-CoV-2 has been detected in the blood of COVID-19 patients indicating that it can reach the bloodstream and potentially infect other organs (Puelles, Lutgehetmann et al. 2020 ).

Once in the bloodstream, the virus can quickly infect endothelial cells throughout the vasculature as they express the ACE2 receptor (Hamming, Timens et al. 2004 , Hamming, Cooper et al. 2007 ). In addition, human brain endothelial cells also express NRP1 (Wang, Cao et al. 2016 ). Postmortem analyses of patients who died from COVID-19 have shown that SARS-CoV-2 can infect endothelial cells and produce endotheliitis in the lungs, heart, kidney, liver and small intestine (Varga, Flammer et al. 2020) . Moreover, experimental studies have also shown that SARS-CoV-2 can infect and replicate in human blood vessel organoids (Monteil, Kwon et al. 2020) , strengthening the hypothesis that blood-borne viruses can reach the brain through the endothelial cells of the brain.

Even if bloodborne virus and bacteria are present in the circulatory system, infections of the brain are not common occurrences due to the presence of the BBB. The function of the BBB, with brain microvascular endothelial cells (BMVECs) being one of its principal components, is to protect the brain and maintain homeostasis by regulating the traffic of substances into and out of the brain and preventing the entrance of pathogens present in the bloodstream (Hawkins and Davis 2005) . To infect the brain via the hematogenous route, the virus must first bypass the BBB. Expression of the ACE2 receptor (Hamming, Timens et al. 2004) , and NRP1 (Wang, Cao et al. 2016 ) has also been confirmed in human BMVECs, making them potential targets for SARS-CoV-2 infection (although TMPRSS2 has not yet been identified in these tissues). To date, at least one study has described via post-mortem analysis of the brain by transmission electron microscopy, the presence of viral-like proteins inside BMVECs in the frontal lobe of a patient who died from COVID-19 (Paniz-Mondolfi, Bryce et al. 2020 ). This provides the first direct evidence that SARS-CoV-2 can infect BMVECs of the BBB, although the origin of the infection (brain or blood) is unclear.

Limited evidence exists about the effects of other types of coronaviruses on the BBB. Laboratory animal studies have shown that MHV induces BBB breakdown regulated by a decrease in the tight junction proteins occludin and ZO-1, resulting in a CNS infection (Bleau, Filliol et al. 2015) . In the owl monkey (Aotus trivirgatus), infection with the coronavirus JHM OMP1 via intracerebral, intranasal or intravenous inoculation resulted in CNS infection, as evidenced by the detection of viral products in the brains of all animals, predominantly in the blood vessels and perivascular regions; this suggests that a coronavirus can infect and replicate in endothelial cells to bypass the BBB (Cabirac, Soike et al. 1993 , Cabirac, Soike et al. 1994 . Moreover, in vitro studies later demonstrated that coronavirus JHM OMP1 can infect cultured BMVECs isolated from humans and rhesus macaques (Cabirac, Murray et al. 1995) , providing further evidence that certain coronaviruses can infect BMVECs of the BBB.

Preliminary evidence suggests SARS-CoV-2 can invade BMVECs in humans (Paniz-Mondolfi, Bryce et al. 2020 ). In addition, a recent study, although pre-print, indicates that the spike protein of SARS-CoV-2 can induce an increase in BBB permeability in a BBB-on-a-chip in vitro system (Buzhdygan, DeOre et al. 2020) . Most importantly, emerging evidence from human studies indicates that SARS-CoV-2 induces BBB dysfunction in humans. Bellon and colleagues recently reported that, from 31 COVID-19 patients with neurological manifestations, 58% presented an increase in BBB permeability (Bellon, Schweblin et al. 2020) , providing the first-in-human evidence that SARS-CoV-2 induces BBB dysfunction. In this study, it was unclear if the disruption of the BBB was a direct result of SARS-CoV-2 infection, or if this damage was a secondary response to neuroinflammation. More research is needed to elucidate the mechanisms by which this virus bypasses the BBB and enters the brain and whether patients with underlying conditions that affect the BBB are at an increased risk of brain infections. For example, brain expression of NRP1 increases after ischemic (Zhang, Tsang et al. 2001) , vascular (Klagsbrun, Takashima et al. 2002) and mechanical injuries (Skold, Cullheim et al. 2000) , which would make these patients potentially more susceptible to brain infection. Once inside the brain, SARS-CoV-2 may be able to cause CNS infection, as receptors for virus entry (NRP1, ACE2 and BSG) and viral modification (CTSL, TMPRSS2 and others) are present in the human brain (Atlas 2020 ) and viral-like particles have also been detected in neurons of postmortem COVID-19 brains (Paniz-Mondolfi, Bryce et al. 2020). Moreover, clinical evidence suggests that SARS-CoV-2 does reach the brain, since multiple neurological manifestations of COVID-19 continue to be reported, including meningitis (Moriguchi, Harii et al. 2020) , ischemic strokes (Beyrouti, Adams et al. 2020 , Oxley, Mocco et al. 2020 , intracerebral hemorrhages (Mao, Jin et al. 2020 , Sharifi-Razavi, Karimi et al. 2020 , Guillain-Barre syndrome (Coen, Jeanson et al. 2020 , Toscano, Palmerini et al. 2020 , Zhao, Shen et al. 2020 , and acute hemorrhagic necrotizing encephalopathy (Poyiadji, Shahin et al. 2020 ). These last two neurological manifestations may result from an exacerbated immune response to the virus that may be independent of CNS infection rather than an inflammatory response, which is thought to be responsible for some of the neurological symptoms in COVID-19. (Poyiadji, Shahin et al. 2020) .

Multiple lines of evidence indicate that infection with SARS-CoV-2 can have a CNS component. It is unclear if this is part of the "core pathology" or if it is restricted to a small number of patients with the most advanced symptoms. Unfortunately, the common occurrence of hypoxia in advanced cases, as well as blood clots, and cytokine "storms" makes it difficult to determine what CNS complications are the result of a CNS infection, as opposed to having a peripheral origin. Furthermore, BMVECs express the ACE2 and NRP1 receptors, implying that viruses which reach the bloodstream have the potential to infect and damage the BBB. This can lead to an infection of the brain, "leakage" in the BBB, and could disrupt vital nutrient exchange between the brain and bloodstream. Unfortunately, animal models may be of little value in evaluating the contribution of CNS infection to CNS pathology in cases of COVID-19. Protein data suggests that humans express little ACE2 and TMPRSS2 in the CNS, whereas rodents (Atlas 2020) and humanized mice are known to display higher levels than humans (Tseng, Huang et al. 2007 , Netland, Meyerholz et al. 2008 . Modeling a non-ACE2/TMPRSS2 CNS infection would require the manipulation of multiple genes in a spatially restricted manner. Differences in the density and distribution of ACE2, TMPRSS2, CTSL, NRP1, and BSG in the brain and periphery mean that humanized rodent models cannot be used to accurately predict the spread of SARS-CoV-2 in the CNS. Moreover, traditional post-mortem analysis of brains from individuals who died of COVID-19 may also be of limited value.

The high incidence of hypoxia induced brain damage and other peripheral events which can damage the brain, makes it very difficult to detected evidence of SARS-CoV-2 related CNS infection. Also, in post-mortem studies the interval from infection to tissue collection is not consistent. Further, an absence of the virus in the brain does not necessary rule out a CNS infection; it rules out a CNS infection as the time of death. The distribution of entry proteins will ultimately determine the extent to which the virus can impact cells within the CNS. For instance, if only 1 in 1,000 cells expresses an entry protein, and these cells are scattered throughout the brain in multiple cell types, then the virus may not have a major lasting impact on CNS function in a healthy adult. However, if its presence is restricted to a cellular subtype or region, the impact of infection could be much greater even if relatively few cells actually die from infection. The most effective approach to determining the potential damage caused by a CNS infection of SARS-CoV-2 may be to determine the relative distribution of ACE2 and alternative viral entry candidates (NRP1 and BSG) in the human brain, as well as what type of brains cells express these proteins. Similarly, it will be necessary to determine the location of modifying proteins (TMPRSS2, CTSL) to determine if the conditions for post-shedding viral modification exist. This could be done with selective immunohistopathology on post-mortem tissue. Currently, fighting the spread and respiratory complications of infection are the greatest priority in the battle against COVID-19. However, as the pandemic shifts and survivors of the infection increasingly outnumber those with active infections, it will become increasingly important to understand the other ways COVID-19 may have resulted in lasting effects on the human body, including the brain. This allows for viral spread from the periphery into the CNS. The OB has many connections throughout the brain. This allows for rapid viral transit to many areas in the brain. Figure 2 . Proposed mechanism of SARS-CoV-2 brain infection via the hematogenous route. Viral particles of SARS-CoV-2 present in the lungs can infect the lung capillaries and be translocated to the pulmonary microcirculation. Viral particles in the bloodstream can then reach the brain through the blood-brain barrier (BBB) by infecting and replicating inside brain microvascular endothelial cells. Infection of neurons by SARS-CoV-2 as well as an increase in BBB permeability could be responsible for severe neurological symptoms in COVID 19.

Olfactory System. Neuroanatomical Basis of

The Human Protein Atlas

Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms

Two neurotropic viruses, herpes simplex virus type 1 and mouse hepatitis virus, spread along different neural pathways from the main olfactory bulb

Cerebrospinal fluid features in SARS-CoV-2 RT-PCR positive patients

Characteristics of ischaemic stroke associated with COVID-19

Anosmia in COVID-19: A Bumpy Road to Establishing a Cellular Mechanism

Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age

Brain Invasion by Mouse Hepatitis Virus Depends on Impairment of Tight Junctions and Beta Interferon Production in Brain Microvascular Endothelial Cells

A lifetime of neurogenesis in the olfactory system

Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters

Unraveling the sense of smell (Nobel lecture)

SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection

The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in vitro models of the human blood-brain barrier

In vitro interaction of coronaviruses with primate and human brain microvascular endothelial cells

Coronavirus JHM OMP1 pathogenesis in owl monkey CNS and coronavirus infection of owl monkey CNS via peripheral routes

Entry of coronavirus into primate CNS following peripheral infection

Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus

Guillain-Barre syndrome as a complication of SARS-CoV-2 infection

Neuropilin-1 is a host factor for SARS-CoV-2 infection

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system

Deconstructing Olfactory Stem Cell Trajectories at Single-Cell Resolution

The Cellular basis of the loss of smell in 2019-nCoV-infected individuals

Parallel-distributed processing in olfactory cortex: new insights from morphological and physiological analysis of neuronal circuitry

The emerging role of ACE2 in physiology and disease

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Nose, Sinus, Pharynx, and Larynx. Comparative Anatomy and Histology

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

The blood-brain barrier/neurovascular unit in health and disease

Odorant-binding proteins and xenobiotic metabolizing enzymes: implications in olfactory perireceptor events

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells

Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome

Effects of COVID-19 on the Nervous System

Odorant receptor-derived cAMP signals direct axonal targeting

Pretarget axon sorting establishes the neural map topography

Horizontal basal cells are multipotent progenitors in normal and injured adult olfactory epithelium

The role of neuropilin in vascular and tumor biology

Spread of the CVS strain of rabies virus and of the avirulent mutant AvO1 along the olfactory pathways of the mouse after intranasal inoculation

Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT

Possible central nervous system infection by SARS coronavirus

Sustentacular Cell Enwrapment of Olfactory Receptor Neuronal Dendrites: An Update

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

The fine structure of the olfactory mucosa in man

Parainfluenza virus type 1 infects olfactory neurons and establishes long-term persistence in the nerve tissue

The olfactory bulb: coding and processing of odor molecule information

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Effect of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features

Multiorgan and Renal Tropism of SARS-CoV-2

SARS-CoV-2 targets neurons of 3D human brain organoids

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Structural basis of receptor recognition by SARS-CoV-2

COVID-19 and intracerebral haemorrhage: causative or coincidental?

Perspectives on olfactory processing, conscious perception, and orbitofrontal cortex

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration

Neuroinvasive potential of SARS-CoV-2 revealed in a human brain organoid model

Guillain-Barre Syndrome Associated with SARS-CoV-2

Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor

Endothelial cell infection and endotheliitis in COVID-19

Neuropilin-1 modulates interferon-gamma-stimulated signaling in brain microvascular endothelial cells

Nervous system involvement after infection with COVID-19 and other coronaviruses

Angiotensin-converting enzyme 2 in the brain: properties and future directions

Brain lesions induced by experimental intranasal infection of Japanese encephalitis virus in piglets

Coronavirus Tests Science's Need for Speed Limits

Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis

SARS-CoV-2 infects and damages the mature and immature olfactory sensory neurons of hamsters

Up-regulation of neuropilin-1 in neovasculature after focal cerebral ischemia in the adult rat

Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence?

We dedicate this manuscript to all the medical professionals who put themselves in harm's way during the SARS and COVID-19 outbreaks. Thank you. This work was funded by the National Center for Toxicological Research.We would like to thank Sarah Sabatelli for her timely assistance in document translation. We would like to thank Drs. Sherry Ferguson, Tim Flanigan, and Amy Inselman for their comments on this manuscript.Figures were prepared with the Motifolio PPT-Toolkits-Biology-Bundle (Motifolio Inc., Ellicott City, USA).

The authors declare no competing interests, are employed solely by the U.S. government, and are not affiliated or employed with any company having any financial interests relating to the research presented or its implications.This study did not generate/analyze datasets/code This manuscript has been processed for clearing/consent for publication via the FDA document tracking system. However, the contents of this manuscript do not necessarily reflect the views and policies or position of the U.S. Food and Drug Administration, nor does the mention of trade names or commercial products constitute the endorsement or any recommendation for use. The information in these materials is not a formal dissemination of information by FDA.Author Roles:Susan Burks, Elvis Cuevas, and Hector Rosas-Hernandez played a key role in manuscript conceptualization, investigation, writing the original draft and draft editing.Manuel A. Ramirez-Lee played a key role in draft editing and was solely responsible for visualization. John C. Talpos played a key role in manuscript conceptualization, investigation, draft editing, and was responsible for supervision.